Article

Osimertinib- Cardiac Dysfunction with Prolonged QTc Interval: Case Report

2021-02-15

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold>: Osimertinib has improved outcomes and is indicated by Food and Drug Administration (FDA) for epidermal growth factor receptor (EGFR)-mutated lung cancer. Osimertinib use is associated with cardiac-related adverse events, including cardiac dysfunction and or prolonged QTc interval. There is an increasing need for a comprehensive evaluation prior to the initiation...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3bc29b08-7f40-5ad3-81e2-b15fa62b6a67
DOI: 10.21203/rs.3.rs-159215/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Osimertinib- Cardiac Dysfunction with Prolonged QTc Interval: Case ReportDOI 10.21203/rs.3.rs-159215/v1Read

Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.Semantic proximity Read

Possible heart failure caused by osimertinib in a lung cancer patient.Semantic proximity Read

Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.Semantic proximity Read

Cardiovascular events in EGFR-mutation non-small-cell lung cancer patients on osimertinib.Semantic proximity Read

Successful Management of Osimertinib-Induced Heart Failure.Semantic proximity Read

[A Case of Significant Ejection Fraction Reduction and Heart Failure Induced by Osimertinib].Semantic proximity Read

Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib.Semantic proximity Read

Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Results from a Phase IV study in India.Semantic proximity Read

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.Semantic proximity Read

Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.Semantic proximity Read

A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin.Semantic proximity Read

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read